In early 2026, the focal segmental glomerulosclerosis community is closely monitoring the January 13 regulatory milestone regarding the potential label expansion of sparsentan. This 2026 decision follows extensive clinical evaluations in the DUPLEX study, which examined the drug’s ability to achieve a sustained reduction in proteinuria compared to active controls. In early 2026, the...
0 Commentarios
0 Acciones
152 Views
0 Vista previa
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek